Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study

Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. Methods: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Metzner, Thomas, Leitner, Deborah R., Mellitzer, Karin, Beck, Andrea, Sourij, Harald, Stojakovic, Tatjana, Reishofer, Gernot, März, Winfried, Landmesser, Ulf, Scharnagl, Hubert, Toplak, Hermann, Silbernagel, Günther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774139/
https://www.ncbi.nlm.nih.gov/pubmed/35052871
http://dx.doi.org/10.3390/biomedicines10010193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774139/
https://www.ncbi.nlm.nih.gov/pubmed/35052871
http://dx.doi.org/10.3390/biomedicines10010193

Ejemplares similares